Geng Qiu1, Jiancheng Fang, Yunshao He. 1. Da An Gene Diagnosis Center, Sun Yat-sen College of Medical Science, Sun Yat-sen University, 72, Zhong Shan Road II, Guangzhou, China.
Abstract
OBJECTIVES: The change in DNA methylation patterns can be used to distinguish between normal and cancer cells. The aim of the present study was to examine the 5' CpG island methylation patterns of the cancer-testis antigen (CT antigen) gene family, MAGE-As, in hepatocellular carcinoma (HCC), and to develop the DNA demethylation pattern as a novel tumor biomarker. METHODS: We used bisulfite-sequencing PCR (BSP) to map the methylation status of the CpG site among the promoter of the MAGE-A gene family in several HCC cell lines including Hep G2, BEL7402, BEL7404, and BEL7407, and normal peripheral blood white blood cells (WBCs). According to differences of the methylation pattern between HCC cell lines and the control, methylation-special PCRs (MSP) have been developed. The developed MSPs were used to detect the paraffin-embedded slices that were pathologically diagnosed as HCC, hepatocirrhosis, hepatitis, and healthy. RESULTS: We found that several CpG sites among the MAGE-A1 and MAGE-A3 promoters have different methylation patterns in the HCC cell lines as compared to those in normal WBCs. Two sets of MSP primers were designed to distinguish the HCC genomic DNA and normal control cell genomic DNA as novel tumor biomarkers, and the biomarkers were validated on the archived paraffin sections of liver primary tissue. In the detection of 34 HCCs and 17 tumor-free liver tissues, the clinical sensitivity and specificity were 91.2% and 100%, respectively. CONCLUSION: Detection of aberrant methylation patterns of MAGEs CpG islands using MSP may be useful for diagnosis of HCC.
OBJECTIVES: The change in DNA methylation patterns can be used to distinguish between normal and cancer cells. The aim of the present study was to examine the 5' CpG island methylation patterns of the cancer-testis antigen (CT antigen) gene family, MAGE-As, in hepatocellular carcinoma (HCC), and to develop the DNA demethylation pattern as a novel tumor biomarker. METHODS: We used bisulfite-sequencing PCR (BSP) to map the methylation status of the CpG site among the promoter of the MAGE-A gene family in several HCC cell lines including Hep G2, BEL7402, BEL7404, and BEL7407, and normal peripheral blood white blood cells (WBCs). According to differences of the methylation pattern between HCC cell lines and the control, methylation-special PCRs (MSP) have been developed. The developed MSPs were used to detect the paraffin-embedded slices that were pathologically diagnosed as HCC, hepatocirrhosis, hepatitis, and healthy. RESULTS: We found that several CpG sites among the MAGE-A1 and MAGE-A3 promoters have different methylation patterns in the HCC cell lines as compared to those in normal WBCs. Two sets of MSP primers were designed to distinguish the HCC genomic DNA and normal control cell genomic DNA as novel tumor biomarkers, and the biomarkers were validated on the archived paraffin sections of liver primary tissue. In the detection of 34 HCCs and 17 tumor-free liver tissues, the clinical sensitivity and specificity were 91.2% and 100%, respectively. CONCLUSION: Detection of aberrant methylation patterns of MAGEs CpG islands using MSP may be useful for diagnosis of HCC.
Authors: S Hartmann; U Kriegebaum; N Küchler; R C Brands; C Linz; A C Kübler; U D A Müller-Richter Journal: Clin Oral Investig Date: 2013-02-21 Impact factor: 3.573
Authors: Viswanath Gunda; Alexandria P Cogdill; Maria J Bernasconi; Jennifer A Wargo; Sareh Parangi Journal: Surgery Date: 2013-12 Impact factor: 3.982
Authors: Pedro A Andrade Filho; Andrés López-Albaitero; Liqiang Xi; William Gooding; Tony Godfrey; Robert L Ferris Journal: Int J Cancer Date: 2009-10-15 Impact factor: 7.396
Authors: Maté Ongenaert; G Bea A Wisman; Haukeline H Volders; Alice J Koning; Ate Gj van der Zee; Wim van Criekinge; Ed Schuuring Journal: BMC Med Genomics Date: 2008-11-24 Impact factor: 3.063
Authors: Amanda J Craig; Teresa Garcia-Lezana; Marina Ruiz de Galarreta; Carlos Villacorta-Martin; Edgar G Kozlova; Sebastiao N Martins-Filho; Johann von Felden; Mehmet Eren Ahsen; Erin Bresnahan; Gabriela Hernandez-Meza; Ismail Labgaa; Delia D'Avola; Myron Schwartz; Josep M Llovet; Daniela Sia; Swan Thung; Bojan Losic; Amaia Lujambio; Augusto Villanueva Journal: PLoS Genet Date: 2021-06-24 Impact factor: 5.917